Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the publication of a peer-reviewed study detailing the steady-state pharmacokinetic properties of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(R), in Clinical Pharmacology in Drug Development. The study, conducted in 60 healthy volunteers, demonstrated that the sublingual formulation achieves faster absorption, earlier peak plasma concentration and higher dose-normalized bioavailability compared to oral extended-release cyclobenzaprine, supporting its use for long-term bedtime dosing to target nonrestorative sleep in fibromyalgia, reduce pain and improve related symptoms.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. To view the full press release, visit https://ibn.fm/AX1hL.
